pemigatinib

Details

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	October 18, 2024
Call for patient/clinician input closed	December 13, 2024
Submission received	October 18, 2024
Submission accepted	November 01, 2024
Review initiated	November 04, 2024
Draft CADTH review report(s) provided to sponsor for comment	January 20, 2025
Deadline for sponsors comments	January 30, 2025
CDA-AMC review report(s) and responses to comments provided to sponsor	February 28, 2025
Expert committee meeting (initial)	March 12, 2025
Draft recommendation issued to sponsor	March 26, 2025
Draft recommendation posted for stakeholder feedback	April 03, 2025
End of feedback period	April 17, 2025
Final recommendation issued to sponsor and drug plans	May 05, 2025
Final recommendation posted	May 22, 2025
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	May 20, 2025
CDA-AMC review report(s) posted	-

Last Updated : May 22, 2025

Key Milestones²
Milestones title	Date
Submission received	11-Oct-24
Review initiated	11-Oct-24
Expert committee meeting (initial)	20-Mar-25
Draft recommendation posted for stakeholder feedback	11-Apr-25
End of feedback period	29-Apr-25
Final recommendation posted	26-May-25
CDA-AMC review report(s) posted	14-May-25

Last Updated : May 26, 2025

Key Milestones²
Milestones title	Date
Submission received	17-Oct-24
Review initiated	17-Oct-24
Expert committee meeting (initial)	20-Mar-25
Draft recommendation posted for stakeholder feedback	11-Apr-25
End of feedback period	29-Apr-25
Final recommendation posted	16-May-25
CDA-AMC review report(s) posted	23-Apr-25

Last Updated : May 26, 2025

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	17-Oct-24
Call for patient/clinician input closed	06-Dec-24
Submission received	27-Nov-24
Submission accepted	11-Dec-24
Review initiated	12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	09-Apr-25
Deadline for sponsors comments	15-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	28-May-25
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25
Final recommendation issued to sponsor and drug plans	03-Jul-25
Final recommendation posted	23-Jul-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	17-Jul-25
CDA-AMC review report(s) posted	-

Last Updated : July 24, 2025

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	17-Oct-24
Call for patient/clinician input closed	06-Dec-24
Submission received	27-Nov-24
Submission accepted	11-Dec-24
Review initiated	12-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	26-Mar-25
Deadline for sponsors comments	04-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	29-May-25
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25
Final recommendation issued to sponsor and drug plans	03-Jul-25
Final recommendation posted	21-Jul-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	17-Jul-25
CDA-AMC review report(s) posted	-

Last Updated : July 21, 2025

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	11-Oct-24
Call for patient/clinician input closed	06-Dec-24
Submission received	25-Nov-24
Submission accepted	09-Dec-24
Review initiated	10-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	25-Mar-25
Deadline for sponsors comments	03-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	28-May-25
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25
Final recommendation issued to sponsor and drug plans	02-Jul-25
Final recommendation posted	18-Jul-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	16-Jul-25
CDA-AMC review report(s) posted	-

Last Updated : July 18, 2025

Last Updated : October 18, 2024

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	11-Oct-24
Call for patient/clinician input closed	06-Dec-24
Submission received	22-Nov-24
Submission accepted	06-Dec-24
Review initiated	09-Dec-24
Draft CADTH review report(s) provided to sponsor for comment	18-Mar-25
Deadline for sponsors comments	27-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	27-May-25
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25
Final recommendation issued to sponsor and drug plans	04-Jul-25
Final recommendation posted	22-Jul-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	18-Jul-25
CDA-AMC review report(s) posted	-

Last Updated : July 22, 2025

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	04-Oct-24
Call for patient/clinician input closed	02-Dec-24
Submission received	14-Nov-24
Submission accepted	28-Nov-24
Review initiated	29-Nov-24
Draft CADTH review report(s) provided to sponsor for comment	21-Feb-25
Deadline for sponsors comments	04-Mar-25
CDA-AMC review report(s) and responses to comments provided to sponsor	28-Mar-25
Expert committee meeting (initial)	09-Apr-25
Draft recommendation issued to sponsor	23-Apr-25
Draft recommendation posted for stakeholder feedback	01-May-25
End of feedback period	15-May-25
Final recommendation issued to sponsor and drug plans	03-Jun-25
Final recommendation posted	19-Jun-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	17-Jun-25
CDA-AMC review report(s) posted	-

Last Updated : June 20, 2025

Key Milestones²
Milestones title	Date
Call for patient/clinician input open	04-Oct-24
Call for patient/clinician input closed	02-Dec-24
Submission received	18-Dec-24
Submission accepted	09-Jan-25
Review initiated	10-Jan-25
Draft CADTH review report(s) provided to sponsor for comment	28-Mar-25
Deadline for sponsors comments	08-Apr-25
CDA-AMC review report(s) and responses to comments provided to sponsor	02-May-25
Expert committee meeting (initial)	14-May-25
Draft recommendation issued to sponsor	27-May-25
Draft recommendation posted for stakeholder feedback	05-Jun-25
End of feedback period	19-Jun-25
Final recommendation issued to sponsor and drug plans	03-Jul-25
Final recommendation posted	21-Jul-25
Deadline for sponsor to submit redaction requests on draft CADTH review report(s)	17-Jul-25
CDA-AMC review report(s) posted	-

Last Updated : July 23, 2025